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Abstract: Implanting glaucoma tubes through the pars plana in the setting of a corneal transplant 
is becoming more common, and there are unique problems associated with such a procedure. 
A 42-year-old man with multiple previous eye surgeries presented with a nonfunctioning pars 
plana glaucoma tube. There was no view to the tube tip, but it was presumed to be clogged 
with ﬁ  brin. Intravitreal tissue plasminogen activator (tPA) was injected through the pars plana 
which resulted in intraocular pressure control without further surgery. This new application of 
intravitreal tPA has not been reported previously. Future research should investigate the optimal 
effective and safe dose of intravitreal tPA injection to relieve such occlusions.
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Introduction
Penetrating keratoplasty (PKP) with concurrent anterior chamber placement of a glau-
coma tube shunt is associated with a high rate of corneal decompensation.1 Recently, 
the Cornea Glaucoma Implant Study Group demonstrated that in patients requiring a 
corneal transplant and a glaucoma tube shunt, the incidence of graft failure and immu-
nologic rejection was decreased with pars plana insertion of the tube.2 We describe 
a novel application of tissue plasminogen activator (tPA) in the management of an 
occluded pars plana glaucoma drainage device.
Case report
A 59-year-old African American male had a history of keratoconus with two prior 
PKPs, cataract extraction with lens implantation, and a failed trabeculectomy in his left 
eye. He presented with an opaque, vascularized cornea and secondary angle-closure 
glaucoma. His vision was hand motions and intraocular pressure (IOP) was 40 mmHg 
by Tonopen (Reichert, Depew, NY). Under general anesthesia, he underwent elective 
combined Eckardt temporary keratoprosthesis, pars plana vitrectomy, placement of   
an Ahmed Glaucoma Valve (New World Medical, Rancho Cucamonga, CA) through 
the pars plana and PKP.
On the ﬁ  rst postoperative day, the IOP was 32 mmHg, the area over the Ahmed 
plate was ﬂ  at, and the anterior chamber had diffuse ﬁ  brin formation. The following 
day, the IOP climbed to 48 mmHg despite oral acetazolamide as well as dorzolamide 
hydrochloride 2%, timolol maleate 0.5%, and brimonidine tartrate 0.15% eyedrops. 
Suspecting a kink in the tube or vitreous incarceration, the patient was returned to the 
operating room where the tube was ﬂ  ushed easily and was repositioned through a new 
sclerostomy along the pars plana.
The IOP improved initially, but by one week rose to 40 mmHg despite maximal medical 
therapy, and there was no elevation over the Ahmed plate (Figure 1). The patient’s intense Clinical Ophthalmology 2009:3 92
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ﬁ  brinoid reaction in the anterior chamber, even on 100 mg of 
oral prednisone daily, precluded an adequate view to the tube 
and suggested that ﬁ  brin was occluding the tube lumen.
Recombinant tissue plasminogen activator (tPA, Genen-
tech Inc, South San Francisco, CA) was injected with a 
30-gauge needle 3.5 mm posterior to the limbus. A total of 
0.1 cc (12.5 µg) was injected. The next day, the IOP was 
9 mmHg, and the bleb over the Ahmed plate was elevated. 
Five months later, visual acuity improved to 20/50, and IOP 
was 17 mmHg on brimonidine tartrate 0.15% twice daily and 
betaxolol 0.25% twice daily. The corneal graft was clear, a 
pseudocapsule had formed around the Ahmed plate and the 
tip of the Ahmed tube was well-visualized (Figure 2).
Discussion
Tissue plasminogen activator (tPA), a stimulator of 
fibrinolysis, has been used both subconjunctivally and 
intracamerally following glaucoma surgery since 1992.3 
There are no prior reports of intravitreal tPA injection fol-
lowing glaucoma surgery. 
Zalta and colleagues reported the largest study using 
intracameral tPA for occluded or near-occluded limbal 
glaucoma drainage devices with 89% of subjects (n = 36) 
achieving success, deﬁ  ned as avoiding the need for additional 
glaucoma surgery.4 In their study, patients received a mean 
of 1.6 injections with a mean tPA dose of 15.9 ± 9.9 µg per 
injection. Six patients had signiﬁ  cant complications (severe 
hyphema, hypotony, anterior chamber ﬂ  attening), which all 
occurred after injections that were administered within 5 days 
after glaucoma surgery.
An important consideration with a pars plana glaucoma 
tube after corneal surgery, as in our case, is that the tube tip 
may not be visible in the immediate postoperative period due 
to corneal edema and/or anterior chamber ﬁ  brin. Zalta and 
Figure 1 Slit lamp photographs of superotemporal bulbar conjunctiva of the left eye. (A) Before the intravitreal tPA injection, conjunctiva was ﬂ  at over the Ahmed plate. Note 
the pericardium (Tutoplast, Costa Mesa, CA) and plate markings. (B) Two months following intravitreal tPA injection, there is a pseudocapsule over the functioning drainage 
device. Intraocular pressure is controlled with topical medications.
Figure 2 Slit lamp photographs of the left eye taken two months postoperatively. (A) Clear corneal graft with optic capture of a MA60AC (Alcon, Fort Worth, TX) intraocular 
lens. (B) The tip of the Ahmed tube in the anterior vitreous cavity is not occluded, as visualized by retroillumination.Clinical Ophthalmology 2009:3 93
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colleagues only used tPA on patients who had a visibly 
occluded or visibly near-occluded tube, deﬁ  ned as ﬁ  brin or 
blood within 2 mm of the tube tip.
Tissue plasminogen activator already has other intraop-
erative and postoperative uses for the retinal surgeon, such 
as in displacing submacular hemorrhages, reducing post-
vitrectomy ﬁ  brin formation, and maintaining patent inferior 
iridectomies in eyes with silicone oil.5 However, in both 
animal studies and one human case report, photoreceptor 
toxicity was noted following 50 µg of intravitreal tPA.6,7
Our case demonstrates successful application of intravit-
real tPA in a nonfunctioning pars plana Ahmed tube. Our 
patient achieved IOP control without further intraocular 
surgery. This innovation is particularly relevant because of 
the increasing frequency of implanting Ahmed tubes through 
the pars plana.
We conclude that intravitreal tPA is a useful option for 
patients with nonfunctioning pars plana glaucoma tubes due 
to ﬁ  brin. The procedure can avoid a reoperation on an already 
inﬂ  amed and vulnerable postsurgical eye. Future investiga-
tion should be directed towards the optimal effective and 
safe dose of intravitreal tPA, taking into consideration that 
the medicine will quickly leave the eye once patency of the 
glaucoma tube is reestablished.
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